NCT03855696View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

August 31, 2021

Conditions
Hemophilia
Interventions
BIOLOGICAL

MG1113

MG1113

OTHER

Placebo of MG1113

Placebo of MG1113

Trial Locations (2)

120-752

Yonsei Cancer Center, Yonsei University Severance Hospital, Seoul

Unknown

Korea University Anam Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Dream CIS, Inc.

INDUSTRY

lead

Green Cross Corporation

INDUSTRY